

Anti-TNSF13B (Belimumab), Human IgG1 Antibody

rev 03/21

CATALOG NO.: A2170-100 (100 µg)

BACKGROUND DESCRIPTION: The research-grade biosimilar is a recombinant fully human IgG1 monoclonal antibody that specifically binds to soluble human B lymphocyte stimulator protein (BLyS), also known as B-cell activating factor (BAFF). BAFF belongs to the superfamily of Tumor Necrosis Factor (TNF) and plays a vital role in B-cell maturation and survival. It is produced by several cell types such as neutrophils, dendritic cells, and macrophages. Binding of BLyS to its receptors on the surface of B-cells activates downstream signaling pathways such as NF-κB and MAPK pathways that promote the expression of anti-apoptotic proteins and inhibit apoptosis. The antibody binds to BLyS, prevents the association with its receptors, and thereby reduces the survival of autoantibody-producing B-cells. The original drug received approval from the FDA to treat systemic lupus erythematosus.

ALTERNATE NAMES: LymphoStat B, LymphoStat-B, DTL, BAFF, BLYS, CD257, TALL1, THANK, ZTNF4, TALL-1, TNLG7A, TNFSF20

ANTIBODY TYPE: Monoclonal

CONCENTRATION: Lot specific

HOST/ISOTYPE: Recombinant / IgG1, lambda

SOURCE: CHO cells

IMMUNOGEN: Human TNFSF13B

CAS NUMBER: 356547-88-1

MOLECULAR WEIGHT: 147 kDa

PURIFICATION: Protein A purified

FORM: Liquid

FORMULATION: In PBS, pH 7.5

SPECIES REACTIVITY: Human

STORAGE CONDITIONS: Store at -80 °C

APPLICATIONS AND USAGE: In vitro studies

This information is only intended as a guide. The optimal dilutions must be determined by the user

RELATED PRODUCTS:

Anti-CD20 (Rituximab), Chimeric Antibody (A1049)
 Anti-TNF-α (Golimumab), Human IgG1 Antibody (A2141)
 Anti-TNFSF11 (Denosumab), Human IgG2 Antibody (A2150)
 Anti-TNF-α (Certolizumab Pegol), Humanized Antibody (A2142)
 Anti-TNF alpha (Infliximab), Human IgG1 Antibody (A1097)

FOR RESEARCH USE ONLY! Not to be used on humans.